3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Oligodendroglioma
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Astrocytoma
1
Interventions
Temozolomide
32
Radiotherapy
11
Magnetic Resonance Spectroscopy
11
Carboplatin
10
Bevacizumab
10
Irinotecan
9
Carmustine
9
Filgrastim
8
Erlotinib Hydrochloride
8
Surgical Procedures, Operative
7
sargramostim
5
Imatinib Mesylate
5
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
5
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
5
temsirolimus
4
Vorinostat
4
Sirolimus
4
Procarbazine
4
Peripheral Blood Stem Cell Transplantation
4
O(6)-benzylguanine
4
aldesleukin
3
Thalidomide
3
Iodine-125
3
Immunohistochemistry
3
Gadolinium DTPA
3
Cyclophosphamide
3
Bortezomib
3
Biopsy
3
lonafarnib
2
imetelstat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Oligodendroglioma
×
picropodophyllin
×
Sarcoma
×
Clear all
NCT01721577
2023-05-22
AXL1717
Rush University Medical Center
Phase 1/2
Terminated
10 enrolled
8 charts